Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corynebacterium parvum
- Development stage
- Discontinued
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intratumoral, Intraperitoneal, Intrapleural, Intralesional
01
Overview
Corynebacterium parvum is a heat-killed, inactivated preparation of the bacterium Corynebacterium parvum, used as an immunomodulatory agent. It has been studied for its ability to stimulate the immune system, particularly by enhancing monocyte and natural killer cell activity and promoting interferon gene activation. These effects result in increased resistance to viral infections and have been investigated for antiviral applications as well as adjuvant use in vaccines[1]. In oncology research, Corynebacterium parvum has demonstrated antitumor properties by stimulating host antitumor immune responses when added to cancer vaccines or administered directly; these effects are mediated through both innate (monocytes/NK cells) and adaptive (T cell-mediated) immunity[2][3][4][5]. Its mechanism is considered nonspecific immunostimulation rather than direct cytotoxicity.
- Other names
- attenuated corynebacterium parvum
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on Corynebacterium parvum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corynebacterium parvum.